Back to Search
Start Over
Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation
- Source :
- Experimental hematology. 34(3)
- Publication Year :
- 2005
-
Abstract
- In order to assess the effect of Pegfilgrastim on the duration of neutropenia and clinical outcome of patients after autologous peripheral blood stem cell transplantation (PBSCT), we compared 20 consecutive patients with lymphoma or multiple myeloma receiving a single 6 mg dose of Pegfilgrastim on day 1 posttransplant to a historical control group of 60 patients receiving daily Filgrastim 5 μg/kg starting on day 1 posttransplant. There were 54 M and 26 F, 30 patients with lymphoma and 50 with myeloma, 26 in CR and 54 not in CR. Mean age was 55±10 yrs and 25 had already received a previous autologous transplant. The two groups were matched for disease and disease status, transplant number, age and sex. Cell dose infused tended to be higher in the Pegfilgrastim group (7.16±3.82 vs 10.03±6.25 x106 CD34+ cells/kg, p=0.0575). There were no differences (p>0.05) in time to 0.5 (8 vs 9 days) or 1 (9 vs 9 days) x109/L neutrophils; to 1 % reticulocytes (13 vs 15 days) or 9 (12 vs 14 days) or 10 (30 vs 25 days) g/dL Hb; to 20 (9 vs 9 days) or 100 (20 vs 31 days) x 109/L platelets. The number of days with fever (2.7±2.3 vs 2.3±2.4 days), incidence of infections (all infections; bacteremia; bacterial, fungal or viral infections; FUO), duration of antibiotic therapy (8.7±5.9 vs 8.4±5.9 days), RBC (1.1±1.6 vs 0.9±1.6) and platelet (1.0±1.7 vs 1.2±1.8) transfusions, and time to hospital discharge (14.5±5.3 vs 15.4±5.8 days) were similar in the Pegfilgrastim compared to the Filgrastim group. However, after initial hematopoietic recovery, several differences between the groups became apparent, with the group always showing higher counts compared to the Filgrastim group (p values
- Subjects :
- Cancer Research
medicine.medical_specialty
Blood transfusion
Platelet Engraftment
Filgrastim
Lymphoma
medicine.medical_treatment
Immunology
Antineoplastic Agents
Hematopoietic stem cell transplantation
Neutropenia
Biochemistry
Gastroenterology
Transplantation, Autologous
Polyethylene Glycols
Internal medicine
Granulocyte Colony-Stimulating Factor
Genetics
Medicine
Humans
Molecular Biology
Cyclophosphamide
Multiple myeloma
Etoposide
business.industry
Hematopoietic Stem Cell Transplantation
Cell Biology
Hematology
medicine.disease
Recombinant Proteins
Surgery
Transplantation
Bacteremia
business
Multiple Myeloma
Pegfilgrastim
medicine.drug
Subjects
Details
- ISSN :
- 0301472X
- Volume :
- 34
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Experimental hematology
- Accession number :
- edsair.doi.dedup.....876957173feadb276f6873d7a3b7d3c4